School of Medicine


Showing 1-20 of 47 Results

  • Rajni Agarwal

    Rajni Agarwal

    Professor of Pediatrics (Stem Cell Transplantation)

    Current Research and Scholarly InterestsHematopoietic Stem cell biology-created a SCID mouse model to study engraftment of cord blood derived hematopoietic cells and use of this model to develop gene transfer technology for Fanconi anemia.
    Clinical research interests are to develop new protocols to reduce Toxicity from the conditioning regimens for stem cell transplants, reducing graft vs host disease, treatment of viral infections post transplant and use of manipulated HSC graft in patients who receive haplo donor transplants.

  • Michael Angelo

    Michael Angelo

    Associate Professor of Pathology

    BioMichael Angelo, MD PhD is a board-certified pathologist and assistant professor in the department of Pathology at Stanford University School of Medicine. Dr. Angelo is a leader in high dimensional imaging with expertise in tissue homeostasis, tumor immunology, and infectious disease. His lab has pioneered the construction and development of Multiplexed Ion Beam Imaging by time of flight (MIBI-TOF). MIBI-TOF uses secondary ion mass spectrometry and metal-tagged antibodies to achieve rapid, simultaneous imaging of dozens of proteins at subcellular resolution. In recognition of this achievement, Dr. Angelo received the NIH Director’s Early Independence award in 2014. His lab has since used this novel technology to discover previously unknown rule sets governing the spatial organization and cellular composition of immune, stromal, and tumor cells within the tumor microenvironment in triple negative breast cancer. These findings were found to be predictive of single cell expression of several immunotherapy drug targets and of 10-year overall survival. This effort has led to ongoing work aimed at elucidating structural mechanisms in the TME that promote recruitment of cancer associated fibroblasts, tumor associated macrophages, and extracellular matrix remodeling. Dr. Angelo is the recipient of the 2020 DOD Era of Hope Award and a principal investigator on multiple extramural awards from the National Cancer Institute, Breast Cancer Research Foundation, Parker Institute for Cancer Immunotherapy, the Bill and Melinda Gates Foundation, and the Human Biomolecular Atlas (HuBMAP) initiative.

  • Sally Arai

    Sally Arai

    Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

    Current Research and Scholarly InterestsResearch interest in utilizing post-transplant adoptive cellular immunotherapy to reduce GVHD and relapse in patients with high risk hematologic malignancies.

  • Jonathan S. Berek, MD, MMSc

    Jonathan S. Berek, MD, MMSc

    Laurie Kraus Lacob Professor

    BioLaurie Kraus Lacob Professor
    Stanford University School of Medicine

    Director, Stanford Women’s Cancer Center
    Senior Advisor, Stanford Cancer Institute

    Executive Director, Stanford Health Communication Initiative
    Director, MedArts Films
    Stanford Center for Health Education
    Stanford University

  • Allison Betof Warner, MD, PhD

    Allison Betof Warner, MD, PhD

    Assistant Professor of Medicine (Oncology)

    BioDr. Betof Warner is a board-certified, fellowship-trained medical oncologist with the Cutaneous Oncology Program and an Assistant Professor in the Department of Medicine, Division of Medical Oncology. She also serves as Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy, and co-Director of the Pigmented Lesion and Melanoma Program.

    Clinical interests of Dr. Betof Warner include treatment of advanced melanoma, immunotherapy, and cellular therapies for solid tumors. She has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy, which is expected to become standard of care for immunotherapy-refractory melanoma.

    Dr. Betof Warner serves as the leader of the Melanoma & Cutaneous Oncology Clinical Research Group, with research interests focused on tumor response to immunotherapy. She has been the principal investigator of multiple clinical trials focusing on immunotherapy-refractory melanoma and is internationally recognized for her expertise in central nervous system metastases and the use of novel cellular therapies. Dr. Betof Warner collaborates with investigators around the world in surgery, neuro-oncology, neurosurgery, radiation oncology, and pathology. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), and Melanoma Research Foundation.

    In addition to publishing her research in peer-reviewed journals, Dr. Betof Warner has served as an editorial and grant reviewer for multiple organizations, including the Melanoma Research Foundation. She has authored book chapters and case reports, contributed to national guidelines, and presented her findings at regional, national, and international meetings.

    Dr. Betof Warner is a member of multiple professional organizations and societies, including the American Association for Cancer Research, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer, where she serves on the Early Career Scientist Committee. She is also a member of the American College of Sports Medicine and the European Society for Medical Oncology.

  • Ami Bhatt

    Ami Bhatt

    Associate Professor of Medicine (Hematology) and of Genetics

    Current Research and Scholarly InterestsThe Bhatt lab is exploring how the microbiota is intertwined with states of health and disease. We apply the most modern genetic tools in an effort to deconvolute the mechanism of human diseases.

  • Scott D. Boyd, MD PhD

    Scott D. Boyd, MD PhD

    Stanford Professor of Food Allergy and Immunology and Professor of Pathology

    Current Research and Scholarly InterestsOur goal is to understand the lymphocyte genotype-phenotype relationships in healthy human immunity and in immunological diseases. We apply new technologies and data analysis approaches to this challenge, particularly high-throughput DNA sequencing and single-cell monoclonal antibody generation, in parallel with other functional assays.

  • Eugene Butcher

    Eugene Butcher

    Klaus Bensch Professor of Pathology

    Current Research and Scholarly InterestsOur interests include:
    1) The physiology and function of lymphocyte homing in local and systemic immunity;
    2) Biochemical and genetic studies of molecules that direct leukocyte recruitment;
    3) Chemotactic mechanisms and receptors in vascular and immune biology;
    4) Vascular control of normal and pathologic inflammation and immunity;
    5) Systems biology of immune cell trafficking and programming in tumor immunity.

  • Yueh-hsiu Chien

    Yueh-hsiu Chien

    Professor of Microbiology & Immunology

    Current Research and Scholarly InterestsContribution of T cells to immunocompetence and autoimmunity; how the immune system clears infection, avoids autoimmunity and how infection impacts on the development of immune responses.

  • Kyle Gabriel Daniels

    Kyle Gabriel Daniels

    Assistant Professor of Genetics

    BioKyle obtained his BS in Biochemistry from the University of Maryland College Park in 2010, conducting undergraduate research with Dr. Dorothy Beckett, PhD. He obtained his PhD in Biochemistry with a certificate in Structural Biology and Biophysics. His dissertation is titled "Kinetics of Coupled Binding and Conformational Change in Proteins and RNA" and was completed in the laboratory of Dr. Terrence G. Oas, PhD. Kyle performed postdoctoral training with Dr. Wendell A. Lim, PhD at UCSF studying how CAR T cell phenotype is encoded by modular signaling motifs within chimeric antigen receptors.

    Kyle's lab is interested in harnessing the principles of modularity to engineer receptors and gene circuits to control cell functions.

    The lab will use synthetic biology, medium- and high-throughput screens, and machine learning to: (1) Engineer immune cells to achieve robust and durable responses against various cancer targets, (2) Coordinate behavior of multiple engineered cell types in cancer, autoimmune disease, and payload delivery, (3) Control survival, proliferation, and differentiation of hematopoietic stem cells (HSCs) and immune cells, and (4) Explore principles of modularity related to engineering receptors and gene circuits in mammalian cells.

  • Mark M. Davis

    Mark M. Davis

    Director, Stanford Institute for Immunity, Transplantation and Infection and the Burt and Marion Avery Family Professor

    Current Research and Scholarly InterestsMolecular mechanisms of lymphocyte recognition and differentiation; Systems immunology and human immunology; vaccination and infection.

  • Edgar Engleman

    Edgar Engleman

    Professor of Pathology and of Medicine (Immunology and Rheumatology)

    Current Research and Scholarly InterestsDendritic cells, macrophages, NK cells and T cells; functional proteins and genes; immunotherapeutic approaches to cancer, autoimmune disease, neurodegenerative disease and metabolic disease.

  • C. Garrison Fathman

    C. Garrison Fathman

    Professor of Medicine (Immunology and Rheumatology), Emeritus

    Current Research and Scholarly InterestsMy lab of molecular and cellular immunology is interested in research in the general field of T cell activation and autoimmunity. We have identified and characterized a gene (GRAIL) that seems to control regulatory T cell (Treg) responsiveness by inhibiting the Treg IL-2 receptor desensitization. We have characterized a gene (Deaf1) that plays a major role in peripheral tolerance in T1D. Using PBC gene expression, we have provisionally identified a signature of risk and progression in T1D.

  • Andrew Fire

    Andrew Fire

    George D. Smith Professor of Molecular and Genetic Medicine and Professor of Pathology and of Genetics

    Current Research and Scholarly InterestsWe study natural cellular mechanisms for adapting to genetic change. These include systems activated during normal development and those for detecting and responding to foreign or unwanted genetic activity. Underlying these studies are questions of how a cells can distinguish information as "self" versus "nonself" or "wanted" versus "unwanted".

  • Michael Fischbach

    Michael Fischbach

    Liu (Liao) Family Professor

    Current Research and Scholarly InterestsThe microbiome carries out extraordinary feats of biology: it produces hundreds of molecules, many of which impact host physiology; modulates immune function potently and specifically; self-organizes biogeographically; and exhibits profound stability in the face of perturbations. Our lab studies the mechanisms of microbiome-host interactions. Our approach is based on two technologies we recently developed: a complex (119-member) defined gut community that serves as an analytically manageable but biologically relevant system for experimentation, and new genetic systems for common species from the microbiome. Using these systems, we investigate mechanisms at the community level and the strain level.

    1) Community-level mechanisms. A typical gut microbiome consists of 200-250 bacterial species that span >6 orders of magnitude in relative abundance. As a system, these bacteria carry out extraordinary feats of metabolite consumption and production, elicit a variety of specific immune cell populations, self-organize geographically and metabolically, and exhibit profound resilience against a wide range of perturbations. Yet remarkably little is known about how the community functions as a system. We are exploring this by asking two broad questions: How do groups of organisms work together to influence immune function? What are the mechanisms that govern metabolism and ecology at the 100+ strain scale? Our goal is to learn rules that will enable us to design communities that solve specific therapeutic problems.

    2) Strain-level mechanisms. Even though gut and skin colonists live in communities, individual strains can have an extraordinary impact on host biology. We focus on two broad (and partially overlapping) categories:

    Immune modulation: Can we redirect colonist-specific T cells against an antigen of interest by expressing it on the surface of a bacterium? How do skin colonists induce high levels of Staphylococcus-specific antibodies in mice and humans?

    Abundant microbiome-derived molecules: By constructing single-strain/single-gene knockouts in a complex defined community, we will ask: What are the effects of bacterially produced molecules on host metabolism and immunology? Can the molecular output of low-abundance organisms impact host physiology?

    3) Cell and gene therapy. We have begun two new efforts in mammalian cell and gene therapies. First, we are developing methods that enable cell-type specific delivery of genome editing payloads in vivo. We are especially interested in delivery vehicles that are customizable and easy to manufacture. Second, we have begun a comprehensive genome mining effort with an emphasis on understudied or entirely novel enzyme systems with utility in mammalian genome editing.

  • Matthew Frank

    Matthew Frank

    Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

    BioDr. Matthew Frank, MD, PhD, is an Assistant Professor of Medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University. Dr. Frank predominantly cares for patients with high-risk lymphoma and other blood cancers. He is a lead investigator of clinical trials evaluating the safety and effectiveness of cancer treatments called chimeric antigen receptor (CAR ) T therapy for patients with lymphomas and leukemias. Dr. Frank’s research focuses on developing methods to identify patients who are at high risk for relapse or developing side-effects after receiving CAR T therapy and to understand why these relapses and side-effects occur.

  • Stephen J. Galli, MD

    Stephen J. Galli, MD

    Mary Hewitt Loveless, MD, Professor in the School of Medicine and Professor of Pathology and of Microbiology and Immunology

    Current Research and Scholarly InterestsThe goals of Dr. Galli's laboratory are to understand the regulation of mast cell and basophil development and function, and to develop and use genetic approaches to elucidate the roles of these cells in health and disease. We study both the roles of mast cells, basophils, and IgE in normal physiology and host defense, e.g., in responses to parasites and in enhancing resistance to venoms, and also their roles in pathology, e.g., anaphylaxis, food allergy, and asthma, both in mice and humans.

  • Chris Garcia

    Chris Garcia

    Younger Family Professor and Professor of Structural Biology

    Current Research and Scholarly InterestsStructural and functional studies of transmembrane receptor interactions with their ligands in systems relevant to human health and disease - primarily in immunity, infection, and neurobiology. We study these problems using protein engineering, structural, biochemical, and combinatorial biology approaches.